Results 1 to 10 of about 3,275 (115)

IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis [PDF]

Frontiers in Endocrinology
ObjectivesThis systematic review and meta-analysis was to evaluate and compare the efficacy and safety profiles of IDegLira versus insulin degludec in the management of type 2 diabetes (T2D).MethodsA comprehensive search was systematically conducted ...
Yang Liu, Xuejing Li, Jie Yang, Suhui Qie, Xiaoli Wang, Xianying Wang, Yingying Zheng   +6 more
doaj   +2 more sources

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Clinical Medicine Insights: Endocrinology and Diabetes, 2012
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a ...
Sami N. Nasrallah, L. Raymond Reynolds
doaj   +2 more sources

Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Introduction Once‐weekly basal insulin Fc (BIF) offers a promising alternative to daily basal insulin by reducing injection burden while maintaining glycaemic control.
Saaed Abunada, Sheela Bai, Usha Kumari, F. N. U. Nancy, Areeba Khan, Nikeeta Bai, F. N. U. Shevani, Anusha Bai, Shah Dev, Noshad Zain ul Abiddin, F. N. U. Umer, Abdul Manan, Sadia Habib Bhutto, Salih Abdella Yusuf   +13 more
doaj   +2 more sources

Sensor-Derived Glycemic Metrics in Women with Type 1 Diabetes Using Insulin Degludec Versus Other Basal Insulin Analogs During Pregnancy—A Post Hoc Analysis of the CopenFast Trial [PDF]

Women's Health Reports
Aim: To explore sensor-derived glycemic metrics during pregnancy in women with type 1 diabetes using insulin degludec or other basal insulin analogs.
Julie C. Søholm, Sidse K. Nørgaard, Kirsten Nørgaard, Tine D. Clausen, Peter Damm, Elisabeth R. Mathiesen, Lene Ringholm   +6 more
doaj   +2 more sources

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes [PDF]

Frontiers in Endocrinology, 2023
IntroductionThe aim of this study was to describe appetite and glucose fluctuation in type 2 diabetes mellitus patients initiating treatment with dulaglutide combined with insulin degludec.MethodsThis retrospective study of patients identified adults ...
Jinxin Huang, Fei Hua, Xiaohong Jiang, Xingguang Zhang, Minxing Yang, Long Wang, Xiaolin Huang, Kaiming Luo   +7 more
doaj   +2 more sources

One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India—TRUST (Tresiba real-world use study)

Metabolism Open, 2022
Objective: This post-authorization safety study (PASS) was conducted to evaluate the long-term safety and effectiveness of insulin degludec in patients with diabetes mellitus (DM) requiring insulin therapy in routine clinical practice in India.
Jothydev Kesavadev, L.Sreenivasa Murthy, Tirthankar Chaudhury, Sadasiva Rao Yalamanchi, J. Giri, Sunil Gupta, Sanjeev Phatak, K.D. Modi, Sanjay Chatterjee, Aparna Manjunath, Manjunatha Revanna, Arpandev Bhattacharya   +11 more
doaj   +1 more source

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials

Journal of Diabetes Investigation, 2021
Aims/Introduction To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different baseline characteristics. Materials and Methods Data from two randomized controlled trials were used:
Mitsuhisa Komatsu, Hirotaka Watada, Shizuka Kaneko, Bue F Ross Agner, Tomoyuki Nishida, Kohei Kaku   +5 more
doaj   +1 more source

Degludec insulin: A novel basal insulin

Indian Journal of Endocrinology and Metabolism, 2011
This paper reviews a novel insulin analogue, degludec, which has the potential to emerge as an ideal basal insulin. It reviews the limitations of existing basal insulin and analogues, and highlights the need for a newer molecule.
Sanjay Kalra, Ambika Gopalakrishnan Unnikrishnan, Manash Baruah, Bharti Kalra   +3 more
doaj   +1 more source

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Journal of Diabetes Research, 2022
Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory
Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi   +11 more
doaj   +1 more source

Efficacy and safety of ultra-long-acting insulin degludec

Therapeutic Advances in Endocrinology and Metabolism, 2012
All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control.
Ammar Wakil, Stephen L. Atkin
doaj   +1 more source